Current Epidemiology and Trends in Invasive Haemophilus Influenzae Disease—United States, 2009–2014

Wednesday, June 22, 2016: 2:00 PM
Tikahtnu A, Dena'ina Convention Center
Heidi M. Soeters , Centers for Disease Control and Prevention, Atlanta, GA
Amy Blain , Centers for Disease Control and Prevention, Atlanta, GA
Brooke Doman , New Mexico Department of Health, Santa Fe, NM
Monica M. Farley , Atlanta VA Medical Center, Decatur, GA
Lee H. Harrison , Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
Ruth Lynfield , Minnesota Department of Health, Saint Paul, MN
Lisa Miller , Colorado Department of Public Health and Environment, Denver, CO
Susan Petit , Connecticut Department of Public Health, Hartford, CT
Arthur Reingold , University of California, Berkeley, Berkeley, CA
William Schaffner , Vanderbilt University School of Medicine, Nashville, TN
Ann Thomas , Oregon Health Authority, Portland, OR
Shelley Zansky , New York State Department of Health, Albany, NY
Xin Wang , Centers for Disease Control and Prevention, Atlanta, GA
Elizabeth C. Briere , Centers for Disease Control and Prevention, Atlanta, GA
BACKGROUND:  Invasive Haemophilus influenzae disease can be caused by both encapsulated serotypes and nontypeable bacteria. With the introduction of H. influenzae serotype b (Hib) conjugate vaccines in 1987, there has been a dramatic reduction of Hib disease in young children. We describe the epidemiology and incidence trends of invasive H. influenzae disease in the US during 2009–2014.

METHODS:  Data were collected from active population- and laboratory-based surveillance for invasive H. influenzae disease conducted through Active Bacterial Core surveillance (ABCs) sites during 2009–2014. Isolates were serotyped via slide agglutination and real-time PCR. Case-fatality rates (CFR) were calculated using the proportion of cases with known outcomes as the denominator. Incidence rates per 100,000 population were determined using US Census data for ABCs sites; projected nationwide estimates were standardized for race and age.

RESULTS:  During the surveillance period, ABCs sites reported 4,124 cases of invasive H. influenzae disease among all ages, resulting in an estimated national annual incidence of 1.9 cases per 100,000 population. Incidence was highest among children aged <5 years (6.5) and adults aged ≥65 years (6.4). The largest burden of disease among children aged <5 years was in infants aged <1 year (incidence: 8.8). Nearly half (47%) of disease among infants aged <1 year occurred during the first month of life, 71% of which occurred in preterm or low-birth weight infants. Among children aged <5 years, disease burden was substantially higher in American Indian and Alaska Natives (AI/AN) (incidence: 43.4) than in all other races (incidence: 5.8). The most common clinical syndromes were bacteremic pneumonia (62%) and bacteremia (26%); 7% had meningitis. Overall, 14% of cases were fatal; CFR was highest among adults aged ≥65 years (20%). Incidence and CFR were highest for nontypeable H. influenzae (incidence: 1.3; CFR: 16%), as compared to non-b encapsulated serotypes (incidence: 0.6; CFR: 10%) and Hib (incidence: 0.04; CFR: 4%). Only 1.7% of invasive H. influenzae disease was due to Hib. Serotype f caused the majority (63%) of non-b encapsulated serotypes, with 20% due to serotype a, 17% serotype e, and 0.3% serotype d.

CONCLUSIONS: A considerable burden of invasive H. influenzae disease still affects the oldest and youngest age groups, particularly AI/AN children. Nontypeable H. influenzae currently causes the highest morbidity and mortality.